NR3C1 and COVID-19: Besides identifying drugs that are already being used (e.g. glucocorticoid receptor antagonists) or are being tested in clinical trials (e.g. JAK inhibitors) as COVID-19 therapies, our study supports the potential for drug repositioning of compounds like MEK or ERK inhibitors for treating the COVID-19-associated CS, which in the case of MEK is already being tested in clinical trials.